NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) Short Interest Up 339.8% in December

NovaBay Pharmaceuticals, Inc. (NYSEAMERICAN:NBY) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totaling 1,361,975 shares, a growth of 339.8% from the December 15th total of 309,674 shares. Approximately 1.4% of the company’s shares are short sold. Based on an average daily volume of 3,774,996 shares, the short-interest ratio is currently 0.4 days. Based on an average daily volume of 3,774,996 shares, the short-interest ratio is currently 0.4 days. Approximately 1.4% of the company’s shares are short sold.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the company. Ground Swell Capital LLC bought a new position in NovaBay Pharmaceuticals in the third quarter valued at about $25,000. Apollon Wealth Management LLC bought a new stake in NovaBay Pharmaceuticals during the third quarter valued at approximately $35,000. Finally, C2C Wealth Management LLC grew its position in NovaBay Pharmaceuticals by 78.2% during the second quarter. C2C Wealth Management LLC now owns 98,000 shares of the biopharmaceutical company’s stock valued at $57,000 after buying an additional 43,000 shares during the period. 23.25% of the stock is owned by hedge funds and other institutional investors.

NovaBay Pharmaceuticals Trading Down 2.4%

Shares of NBY stock traded down $0.31 during midday trading on Wednesday, reaching $12.73. 899,496 shares of the stock were exchanged, compared to its average volume of 2,531,755. The firm has a market cap of $1.60 billion, a PE ratio of -1.28 and a beta of 0.09. The company’s 50 day moving average is $3.71 and its two-hundred day moving average is $2.12. NovaBay Pharmaceuticals has a 1 year low of $0.46 and a 1 year high of $19.95.

NovaBay Pharmaceuticals Company Profile

NovaBay Pharmaceuticals, Inc is a clinical-stage biotechnology company focused on developing and commercializing novel, non-antibiotic anti-infective products designed to regulate the innate immune response. Leveraging its proprietary Aganocide® Technology, the company’s synthetic antimicrobial compounds target and neutralize pathogens without contributing to antibiotic resistance. NovaBay’s research and development efforts concentrate on ophthalmic, dermatological and wound care applications, aiming to address unmet needs in infection control and inflammation management.

The company’s primary commercial products include Avenova®, an eyelid and lash cleaning solution indicated for managing chronic blepharitis and meibomian gland dysfunction, and NeutroPhase®, a pure hypochlorous acid wound and skin cleanser used in acute and chronic wound irrigation.